Chiesi Group Forges Alliance with Karolinska Institutet to Tackle Urgent Health Challenges
14 Maggio 2024
Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications
Chiesi Carbon Minimal Inhalers reach new milestone with clinical phase III initiation
03 Aprile 2024
Chiesi Group: a new supplementary labor agreement in Italy puts people and their needs first
18 Marzo 2024
Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi (1940-2024)
05 Marzo 2024
PAST, PRESENT, FUTURE
15 Febbraio 2024
Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy
08 Gennaio 2024
Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® (birch triterpenes) topical gel for the Treatment of Epidermolysis Bullosa
19 Dicembre 2023
Chiesi was awarded the 59° Oscar di Bilancio for the Benefit Corporation category
